It has been recently documented in a growing number of malignancies that tumor mutation burden (TMB) and microsatellite instability status are more informative biomarkers for predicting the response to anti-PD-L1 immunotherapy than PD-L1 immunohistochemical determination [5,6,7]. This evidence concerns the gene CD274 and neoplasm.